ModerateHMG-CoA reductase inhibitors (statins)×Proton pump inhibitors
Updated · Methodology
Mechanism
Omeprazole weakly blocks CYP3A4 – atorvastatin exposure rises modestly (by 10–20%). Clinically significant myopathy beyond baseline is rare.
Symptoms
Usually no changes. In patients with risk factors (older age, chronic kidney disease, hypothyroidism): muscle pain and weakness possible.
Management
The combination is acceptable without dose change. In patients with myopathy risk factors, check creatine kinase on muscle symptoms. Alternative PPI without CYP3A4 effect: pantoprazole or rabeprazole.
Check the full regimen, not just this pair
Opens the checker with these two drugs prefilled. Add the rest of the regimen and recompute additive risks.
Summary of a multi-drug list →
Medicine list: everything you take in one place →
Sources
- Lexicomp: Lexicomp Drug Interactions (2024)– Wolters Kluwer Clinical Drug Information, Inc. Lexi-Interact Online, 2024
- Pharmaceutical Press: Stockley's Drug Interactions, 12th edition (2024)– Preston CL (ed.). Stockley's Drug Interactions. 12th ed. London: Pharmaceutical Press; 2024